NASDAQ:VICL - Vical Stock Price, News & Analysis

$0.85
-0.02 (-2.30 %)
(As of 08/19/2019 04:00 PM ET)
Today's Range
$0.83
Now: $0.85
$0.88
50-Day Range
$0.67
MA: $0.77
$0.86
52-Week Range
$0.66
Now: $0.85
$1.47
Volume9,971 shs
Average Volume710,034 shs
Market Capitalization$19.41 million
P/E RatioN/A
Dividend YieldN/A
Beta0.31
Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VICL
CUSIP92560210
Phone858-646-1100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.62 million
Book Value$1.82 per share

Profitability

Net Income$-16,250,000.00
Net Margins-1,002.10%

Miscellaneous

Employees30
Market Cap$19.41 million
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable

Receive VICL News and Ratings via Email

Sign-up to receive the latest news and ratings for VICL and its competitors with MarketBeat's FREE daily newsletter.


Vical (NASDAQ:VICL) Frequently Asked Questions

What is Vical's stock symbol?

Vical trades on the NASDAQ under the ticker symbol "VICL."

How were Vical's earnings last quarter?

Vical Incorporated (NASDAQ:VICL) issued its earnings results on Tuesday, February, 19th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). The biotechnology company had revenue of $0.12 million for the quarter, compared to analysts' expectations of $0.04 million. Vical had a negative net margin of 1,002.10% and a negative return on equity of 29.46%. View Vical's Earnings History.

When is Vical's next earnings date?

Vical is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Vical.

What price target have analysts set for VICL?

2 equities research analysts have issued 12 month target prices for Vical's shares. Their forecasts range from $4.00 to $4.00. On average, they expect Vical's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 370.6% from the stock's current price. View Analyst Price Targets for Vical.

What is the consensus analysts' recommendation for Vical?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vical in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vical.

Has Vical been receiving favorable news coverage?

News coverage about VICL stock has been trending negative this week, InfoTrie reports. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Vical earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Vical.

Who are some of Vical's key competitors?

What other stocks do shareholders of Vical own?

Who are Vical's key executives?

Vical's management team includes the folowing people:
  • Mr. Vijay B. Samant, CEO, Pres & Director (Age 66)
  • Dr. Lawrence Russell Smith, Sr. VP of Research (Age 58)
  • Mr. Anthony Alan Ramos, VP, CFO & Chief Accounting Officer (Age 52)
  • Dr. Mammen P. Mammen Jr., Former Sr. VP of Clinical Devel. (Age 55)

Who are Vical's major shareholders?

Vical's stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (6.82%), Sio Capital Management LLC (5.82%), BlackRock Inc. (1.49%) and Fosun International Ltd (1.37%). Company insiders that own Vical stock include Armistice Capital Master Fund, Armistice Capital, Llc and Robert C Merton. View Institutional Ownership Trends for Vical.

Which institutional investors are selling Vical stock?

VICL stock was sold by a variety of institutional investors in the last quarter, including Sio Capital Management LLC, BlackRock Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for Vical.

Which institutional investors are buying Vical stock?

VICL stock was purchased by a variety of institutional investors in the last quarter, including Fosun International Ltd. Company insiders that have bought Vical stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc and Robert C Merton. View Insider Buying and Selling for Vical.

How do I buy shares of Vical?

Shares of VICL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vical's stock price today?

One share of VICL stock can currently be purchased for approximately $0.85.

How big of a company is Vical?

Vical has a market capitalization of $19.41 million and generates $1.62 million in revenue each year. The biotechnology company earns $-16,250,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Vical employs 30 workers across the globe.View Additional Information About Vical.

What is Vical's official website?

The official website for Vical is http://www.vical.com/.

How can I contact Vical?

Vical's mailing address is 10390 PACIFIC CENTER COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-646-1100 or via email at [email protected]


MarketBeat Community Rating for Vical (NASDAQ VICL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  249 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  425
MarketBeat's community ratings are surveys of what our community members think about Vical and other stocks. Vote "Outperform" if you believe VICL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VICL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel